Predictive Value of Early HCV RNA Quantitation for Sustained Response in Nonresponders Receiving Daily Interferon and Ribavirin Therapy

Journal of Medical Virology

Volumn 72, Issue 1, 2004, Pages 46-51

  Trimoulet, Pascale ^a   De Lédinghen, Victor ^b   Foucher, Juliette ^b   Castéra, Laurent ^b   Fleury, Hervé ^a   Couzigou, Patrice ^b  

^a HÔPITAL PELLEGRIN   (France)

^b HAUT LÉVÊQUE HOSPITAL   (France)

Author keywords

Daily interferon; Early and sustained response; Hepatitis C virus RNA; Predictive value; Ribavirin

Indexed keywords

RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT ALPHA2B INTERFERON; RIBAVIRIN; VIRUS RNA;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG RESPONSE; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NONHUMAN; PREDICTION; PROGNOSIS; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; RECEIVER OPERATING CHARACTERISTIC; RNA ANALYSIS; VIROLOGY; VIRUS LOAD;

ADULT; AGED; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2B; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; RIBAVIRIN; RNA, VIRAL; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME; VIRAL LOAD;

HEPATITIS C VIRUS;

EID: 20244386501     PISSN: 01466615     EISSN: None     Source Type: Journal    
DOI: 10.1002/jmv.10528     Document Type: Article

References (28)

1. Agence Nationale d'Accréditation et d'Evaluation en Santé (ANAES). 2002. Consensus conference. Treatment of hepatitis C. Gastroenterol Clin Biol 26:B303-B320.
2. Booth JC, O'Grady J, Neuberger J. 2001. Clinical guidelines on the management of hepatitis C. Gut 49(suppl 1):I-1-I-21.
3. Civeira MP, Prieto J. 1999. Early predictors of response to treatment in patients with chronic hepatitis C. J Hepatol 31(suppl 1):237-243.
4. Conjeevaram HS, Everhart JE, Hoofnagle JH. 1995. Predictors of a sustained beneficial response to interferon alpha therapy in chronic hepatitis C. Hepatology 22:1326-1329.
5. Davis GL, Balart LA, Schiff ER, Lindsay K, Bodenheimer HC Jr, Perrillo RP, Carey W, Jacobson IM, Payne J, Dienstag JL, Dienstag JL, VanThiel DH, Tamburro C, Lefkowitch J, Albrecht J, Meschievitz C, Ortego TJ, Gibas A, and the Hepatitis Interventional Therapy Group. 1989. Treatment of chronic hepatitis C with recombinant interferon alpha. A randomized, controlled trial. N Engl J Med 321:1501-1506.
6. de Lédinghen V, Trimoulet P, Winnock M, Bernard PH, Bourlière M, Portal I, Rémy AJ, Szostak N, Lévy S, Tran A, Abergel A, Chêne G, Fleury H, Couzigou P, French Multicenter Study Group. 2002. Daily or three times per week interferon (-2b in combination with ribavirin or interferon alone for the treatment of patients with chronic hepatitis C not responding to previous interferon alone. J Hepatol 36:819-826.
7. Di Bisceglie A. 1998. Hepatitis C. Seminar. Lancet 351:351-355.
8. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Gonqales F Jr, Haussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J. 2002. Peginterferon alpha-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347:975-982.
9. Garson JA, Brillanti S, Whitby K, Foli M, Deaville R, Masci C, Mi M, Barbara L. 1995. Analysis of clinical and virological factors associated with response to alpha interferon therapy in chronic hepatitis C. J Med Virol 46:109-115.
10. Gavier B, Martinez-Gonzalez MA, Riezu-Boj JI, Lasarte JJ, Garcia N, Civeira MP, Prieto J. 1997. Viremia after one month of interferon therapy predicts treatment outcome in patients with chronic hepatitis C. Gastroenterology 113:1647-1653.
11. Hadziyannis SJ, Cheinquer H, Morgan T, Diago M, Jensen DM, Sette H Jr, Ramadori G, Bodenheimer HC, Marcellin P, Lee SD, Roberts PJ, Ackrill AM. 2002. Peginterferon alpha-2a (40kD) (Pegasys) in combination with ribavirin: efficacy and safety results from a phase III, randomized, double-blind, multicentre study examining effect of duration of treatment and ribavirin dose [abstract]. J Hepatol 36(suppl 1):1.
12. Hoofnagle JH, Di Bisceglie AM. 1997. The treatment of chronic viral hepatitis. N Engl J Med 336:347-356.
13. Lai MY, Kao JH, Yang PM, Wang JT, Chen PJ, Chan KW, Chu JS, Chen DS. 1996. Long-term efficacy of ribavirin plus interferon alpha in the treatment of chronic hepatitis C. Gastroenterology 111:1307-1312.
14. Lee WM, Reddy KR, Tong MJ, Black M, van Leeuwen DJ, Holling FB, Mullen KD, Pimstone N, Albert D, Gardner S. 1998. Early hepatitis C virus RNA responses predict interferon treatment outcomes in chronic hepatitis C. Hepatology 28:1411-1415.
15. Lee SS, Heathcote EJ, Reddy KR, Zeuzem S, Fried MW, Wright TL, Pockros PJ, Häussinger D, Smith CI, Lin A, Pappas SC. 2002. Prognostic factors and early predictability of sustained viral response with peginterferon alpha-2a (40KD). J Hepatol 37:500-506.
16. Manns MP, McHutchison J, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling MH, Albrecht JK and the International Hepatitis Interventional Therapy Group. 2001. Peginterferon alpha-2b plus ribavirin compared with interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358:958-965.
17. McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, Goodman ZD, Ling MH, Cort S, Albrecht JK. 1998. Interferon alpha-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 339:1485-1492.
18. National Centers for Disease Control and Prevention. 2003. Hepatitis C fact sheet (http://www.cdc.gov/ncidod/diseases/hepatitis/c/fact. htm).
19. National Institutes of Health Consensus Development Conference Statement: management of hepatitis C: June 10-12, 2002. Hepatology 36:S3-S20.
20. Pagliaro L, Craxi A, Cammaa C, Tine F, Di Marco V, Lo Iacono O, Almasio P. 1994. Interferon-alpha for chronic hepatitis C: an analysis of pretreatment clinical predictors of response. Hepatology 19:820-828.
21. Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, Bain V, Heathcote J, Zeuzem S, Trepo C, Albrecht J. 1998. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 352:1426-1432.
22. Rosen HR, Martin P. 2000. Viral hepatitis in the liver transplant recipient. Infect Dis Clin North Am 3:761-784.
23. Shiffman ML. 2002. Retreatment of patients with chronic hepatitis C. Hepatology 36(suppl 1):S128-S134.
24. Suzuki T, Tanaka E, Matsumoto A, Urushihara A, Sodeyama T. 1995. Usefulness of a simple assay for serum concentration of hepatitis C virus RNA and HCV genotype in predicting the response of patients with chronic hepatitis C to interferon alpha-2a therapy. J Med Virol 46:162-168.
25. Tong MJ, Blatt LM, McHutchison JG, Co RL, Conrad A. 1997. Prediction of response during interferon alpha 2b therapy in chronic hepatitis C patients using viral and biochemical characteristics: a comparison. Hepatology 26:1640-1645.
26. Yamada G, Takatani M, Kishi F, Takahashi M, Doi T, Tsuji T, Shin S, Tanno M, Urdea MS, Kolberg JA. 1995. Efficacy of interferon alpha therapy in chronic hepatitis C patients depends primarily on hepatitis C virus RNA level. Hepatology 22:1351-1354.
27. Zeuzem S, Lee JH, Franke A, Ruster B, Prummer O, Herrmann G, Roth WK. 1998. Quantification of the initial decline of serum hepatitis C virus RNA and response to interferon alpha. Hepatology 27:1149-1156.
28. Zweig MH, Campbell G. 1993. Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin Chem 39:561-577.